Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Financial Instruments Measured at Fair Value on Recurring Basis

The following tables set forth the fair value of the Company’s consolidated financial instruments that were measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023:

	September 30, 2024
	Level 1		Level 2		Level 3		Total
SAFE Note	$	-	$	-	$	1,000,000	$	1,000,000
Total fair value	$	-	$	-	$	1,000,000	$	1,000,000

	December 31, 2023
	Level 1		Level 2		Level 3		Total
SAFE Note	$	-	$	-	$	1,000,000	$	1,000,000
Total fair value	$	-	$	-	$	1,000,000	$	1,000,000

Schedule of Property and Equipment Estimated Useful Lives

Laboratory equipment	5 years
Furniture and fixtures	7 years
Leasehold improvements	Lesser of the lease duration or the life of the improvements

Schedule of Property and Equipment

Property and equipment consist of the following as of September 30, 2024 and December 31, 2023, respectively:

	September 30, 2024			December 31, 2023
Laboratory equipment	$	1,067,241		$	885,696
Furniture and fixtures		54,338			49,838
Leasehold improvements		279,161			279,161
Total property and equipment		1,400,740			1,214,695
Less: Accumulated depreciation		(661,134	)		(461,319	)
Property and equipment, net	$	739,606		$	753,376

Schedule of Grants Receivable Activity

Summary of grants receivable activity for the nine months ended September 30, 2024 and 2023, is presented below:

	2024			2023
Balance at beginning of period	$	882,319		$	809,532
Grant costs expensed		1,756,852			2,180,581
Grants for equipment purchased		6,379			-
Grant fees		50,854			84,827
Grant funds received		(2,142,441	)		(2,398,488	)
Balance at end of period	$	553,963		$	676,452